Skip to content

Effects of E-smoke on Levels of Endothelial Progenitor Cells and Microparticles in Healthy Volunteers

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02532894
Acronym
ESMOKE
Enrollment
16
Registered
2015-08-26
Start date
2014-10-31
Completion date
2016-03-31
Last updated
2021-10-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Keywords

endothelial dysfunction, microvesicles, endothelial progenitor cells, electronic cigarettes

Brief summary

We plan to investigate the acute effects of inhaling e-cigarette vapor on cell function measured by microvesicles and endothelial progenitor cells. Micro vesicles are released upon either activation or apoptosis from different cell types such as platelets, leucocytes and endothelial cell. Endothelial progenitor cells are a type of stem cells that circulate in the blood with the ability to differentiate to endothelial cells. Endothelial progenitor cells are inversely correlated to cardiovascular risk factors. As a secondary endpoint we plan to investigate exhaled nitric oxide - a common inflammation marker used in asthmatic patients - after inhalation of electronic cigarette vapor.

Interventions

DEVICEElectronic cigarette

Inhaling e-cigarette vapor

Sponsors

Karolinska Institutet
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 35 Years
Healthy volunteers
Yes

Inclusion criteria

* healthy subjects * sporadic cigarette smoking (\<9 cigarettes per month)

Exclusion criteria

* Any form of cardiovascular disease * Any form of pulmonary disease like asthma or COPD * Any form of systemic or chronic disorder like rheumatologic or metabolic diseases. * Active allergy within 4 weeks of the study * Symptoms of infection or inflammation within 4 weeks of the study * Pregnancy

Design outcomes

Primary

MeasureTime frame
Change in number of endothelial progenitor cells24 hours
Change in number of micro vesicles24 hours

Secondary

MeasureTime frame
Change in exhaled nitric oxide24 hours

Countries

Sweden

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026